BMC Urology works with with Cochrane Urology in providing our authors with expert advice on systematic reviews and meta-analyses
Designing the selenium and bladder cancer trial (SELEBLAT), a phase lll randomized chemoprevention study with selenium on recurrence of bladder cancer in Belgium
In Belgium, bladder cancer is the fifth most common cancer in males (5.2%) and the sixth most frequent cause of death from cancer in males (3.8%). Previous epidemiological studies have consistently reported th...
Citation: BMC Urology 2012 12:8